marked.bio

EGFR-MET bispecific antibody · bispecific antibody

MCLA-129

3 active trials across 3 of our biomarkers, targeting EGFR x c-MET. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 3 3 Phase 2
EGFR exon 20 insertion 1 1 Phase 1/2
MET exon 14 skipping 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of MCLA-129.

  1. Betta Pharmaceuticals 3

Trials

3 of 3 trials shown

  1. Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

    Not yet recruiting Phase 2 Betta Pharmaceuticals Started 2025Primary completion 2028-04 NCT06885840

    MCLA-129

    …Cohort 2: Patients with advanced NSCLC with previously detected EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation) who have progressed after prior standard treatment which inclu…

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  2. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

    Recruiting Phase 1/2 Betta Pharmaceuticals Started 2021Primary completion 2028-04 NCT04930432

    MCLA-129

    For patients with advanced NSCLC, EGFR positive is defined as: EGFR mutation or EGFR amplification.

    EGFR exon 19 deletion / L858REGFR exon 20 insertionMET exon 14 skippingSolid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer

  3. Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

    Not yet recruiting Phase 1 Betta Pharmaceuticals Started 2023Primary completion 2028-11 NCT06015568

    MCLA-129befotertinib

    …astatic NSCLC that is not suitable for radical surgery or radiotherapy, and harbored EGFR exon 19 deletion or exon 21 L858R mutation( either alone or in combination with other EGFR mutations) in N…

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2023-08-29Non-Small Cell Lung Cancer、EGFR Sensitive Mutation